Search results
Results from the WOW.Com Content Network
Rituximab, sold under the brand name Rituxan among others, is a monoclonal antibody medication used to treat certain autoimmune diseases and types of cancer. [18] It is used for non-Hodgkin lymphoma, chronic lymphocytic leukemia (in children and adults, but not recommended in elderly patients), rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura ...
Cytokine reaction syndrome may also be induced by certain medications, such as the CD20 antibody rituximab and the CD19 CAR T cell tisagenlecleucel. The experimental drug TGN1412—also known as Theralizumab—caused extremely serious symptoms when given to six participants in a Phase I trial. [2]
But it may also cause side effects like skin irritation (particularly with gels), a high red blood cell count, acne, hair loss, and male infertility. TRT has also been linked by some reports to ...
These side-effects can frequently be reduced or eliminated with antiemetic drugs. Low-certainty evidence also suggests that probiotics may have a preventative and treatment effect of diarrhoea related to chemotherapy alone and with radiotherapy. [ 86 ]
It is a promising treatment of renal diseases with proteinuria, in particular patients with resistance or partial response to rituximab. [10] A single low-dose infusion of Obinutuzumab, found to be effective and safe in inducing prolonged remission in children with steroid-dependent or frequently relapsing nephrotic syndrome.
Common side effects include fever, infection, cough, headache, trouble sleeping, and rash. [30] Other severe side effects include heart failure, allergic reactions, and lung disease. [30] Use during pregnancy may harm the baby. [22] Trastuzumab works by binding to the HER2 receptor and slowing down cell replication. [30]
Basiliximab is indicated for the prophylaxis of acute organ rejection in de-novo allogeneic renal transplantation. [3] It is to be used concomitantly with ciclosporin for microemulsion- and corticosteroid-based immunosuppression, in people with panel reactive antibodies less than 80%, or in a triple maintenance immunosuppressive regimen containing ciclosporin for microemulsion, corticosteroids ...
The combination had an acceptable safety profile; the main side effects were gastrointestinal disorders and there were no clinically relevant drug–drug interactions. [ 4 ] In a phase II study, 73 patients with stage IIIB/IV cancer were randomly assigned to 250mg or 150mg BIBF 1120 monotherapy twice-daily. [ 5 ]